You can buy or sell Xencor and other stocks, options, ETFs, and crypto commission-free!
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. Read More The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Xencor
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inh...
Markets InsiderMar 8
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Xencor and Genentech entered the agreement to develop and commercialize novel ...
The Motley FoolMar 3
3 Top Biotech Stocks to Buy Right Now
It's hard to beat the world of biotech investing when it comes to sheer excitement. Biotechs announce major news almost on a daily basis, whether it's clinical updates, deals, or financial reports. But while some investors might like the excitement, every investor likes a shot at making a solid return. We asked three Motley Fool contributors to pick the biotech stocks that they think provide great prospects of generating those solid returns that investors crave. Here's why they chose Celgene (NASDAQ:CELG),...
Expected May 6, After Hours